The emergence of targeted therapies in oncology brings an increased need for companion diagnostic tests. Companion diagnostics are medical devices that help physicians to decide the treatments and effective dosage for patients and which are tailored specifically to the patient. It is an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics (CDx) are the molecular tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with targeted therapeutic medicines. These diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to the patients.
The global companion diagnostic testing market report estimates the market size (Revenue US$ million – 2014 to 2021) for market segmentation based on indication or disease type (breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global companion diagnostic testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global companion diagnostic testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global companion diagnostic testing market and included in this report are Roche Holdings AG, Abbott Laboratories, Genomic Health, Inc., Qiagen N.V., Life Technologies Corporation, Agilent Technologies, Inc. and GE Healthcare, Ltd.